Get started
Author

L.P. del Carpio

Observed names: L. Del Carpio, L. Del Carpio Huerta, L. Pl Carpio De Huerta, L. PlCarpio De Huerta, L. del Carpio, L. del Carpio Huerta, L.P. Del Carpio, L.P. de Carpio Huerta, L.P. del Carpio Huerta, Luis Del Carpio, Luis Del Carpio Huerta, Luis P Del Carpio, Luis P. Del Carpio, Luis P. Del Carpio Huerta, Luis P. del Carpio, Luis Paul Del Carpio Huerta, Luis Paul del Carpio, Luis del Carpio, Luís del Carpio, P. del Carpio Luis
Observed institutions: Universitat Autònoma de Barcelona, Hospital de Sant Pau, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Duran i Reynals Hospital, Universitat de Barcelona
ORCID: 0000-0001-9017-2460
Observed ORCID: 0000-0001-9017-2460
OpenAlex ID: A5111062209
Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration
2017 · Ariadna Tibau, Consolación Molto, et al. · JNCI Journal of the National Cancer Institute · 89
PDF
Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents
2020 · Mariona Riudavets, Joaquin Mosquera, et al. · Frontiers in Oncology · 55
PDF
Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis
2023 · J.M. Piulats, C. Watkins, et al. · Annals of Oncology · 45
PDF
Additive Role of Immune System Infiltration and Angiogenesis in Uveal Melanoma Progression
2021 · Sandra García-Mulero, Maria Henar Alonso, et al. · International Journal of Molecular Sciences · 43
PDF
Correlation between immune-related adverse events (irAEs) and efficacy in patients with solid tumors treated with immune-checkpoints inhibitors (ICIs).
2018 · Mariona Riudavets, Andrés Barba, et al. · Journal of Clinical Oncology · 32
Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer
2025 · Esra Güç, Agatha Treveil, et al. · Nature Communications · 19
Brain metastases in colorectal cancer: prognostic factors and survival analysis
2018 · Luis Del Carpio Huerta, Anna Cristina Virgili Manrique, et al. · International Journal of Colorectal Disease · 19
Detection of the Uveal Melanoma-Associated Mutation GNAQ Q209P from Liquid Biopsy Using CRISPR/Cas12a Technology
2023 · Carmen Escalona-Noguero, Hernán Alarcón-Iniesta, et al. · Analytical Chemistry · 15
Driver mutations in GNAQ and GNA11 genes as potential targets for precision immunotherapy in uveal melanoma patients
2023 · Sandra García-Mulero, Roberto Fornelino, et al. · OncoImmunology · 11
PDF
Differences in glucose metabolic activity in liver metastasis separates two groups of metastatic uveal melanoma patients with different prognosis
2023 · Luis P. del Carpio, María Asunción Algarra, et al. · Cancer Medicine · 11
PDF
Molecular determinants of survival in metastatic uveal melanoma: The impact of SF3B1 mutations
2025 · Luis P. del Carpio, Mar Varela, et al. · European Journal of Cancer · 8
667P Impact of pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) on overall survival (OS) in patients (p) with metastatic castration-sensitive prostate cancer (mCSPC) treated with docetaxel (D) plus androgen-deprivation therapy (ADT)
2020 · L. Notario, J.M. Piulats, et al. · Annals of Oncology · 2
PDF
Comment on: “Tebentafusp Versus Nivolumab Plus Ipilimumab for Metastatic Uveal Melanoma: An E‑Value Sensitivity Analysis Assessing Effect of Unmeasured Confounders on Observational Associations”
2025 · Claire Watkins, Luis del Carpio, et al. · Clinical Drug Investigation · 1
1080MO Sitravatinib plus tislelizumab for metastatic uveal melanoma with liver metastasis: The open-label, multicenter, phase II GEM-2101 trial
2024 · L.P. de Carpio Huerta, E. Espinosa, et al. · Annals of Oncology · 1
PDF
1133P SF3B1 mutation predicts improved overall survival in metastatic uveal melanoma patients: Molecular and clinical correlates
2023 · L.P. del Carpio Huerta, M. Varela, et al. · Annals of Oncology · 1
PDF
P-153 Safety and effectiveness of sorafenib in elderly patients diagnosed with advanced hepatocellular carcinoma in a monographic oncologic center
2021 · Z. Vidales Sepulveda, N. Gómez Serra, et al. · Annals of Oncology · 1
PDF
Afatinib dose intensity and clinical efficacy in advanced EGFR-mutated non-small cell lung cancer: UK multicentre real-life data
2018 · C. Escriu, M. Sallam, et al. · Annals of Oncology · 1
A novel KRAS mutation in metastasic conjunctival melanoma: a case report and literature review
2017 · Luis P. Del Carpio Huerta, Maria Mas Castells, et al. · Melanoma Research · 1
Comparison of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) in clinical trials supporting US Food and Drug Administration (FDA) approval of orphan vs. non-orphan drugs
2017 · C. Molto Valiente, A. Tibau, et al. · Annals of Oncology · 1
Brain metastases (BM) in colorectal cancer (CRC): Prognostic factors and survival analysis
2016 · L. Pl Carpio De Huerta, M. Tobeña, et al. · Annals of Oncology · 1
Corrigendum to “Molecular determinants of survival in metastatic uveal melanoma: The impact of SF3B1 mutations” Eur J Cancer 226 (August) (2025) 115591
2026 · Luis P. Del Carpio, Mar Varela, et al. · European Journal of Cancer
PDF
Anti–PD-1 (PD-1) monotherapy versus combination with anti–CTLA-4 for metastatic uveal melanoma (MUM) patients (pts).
2026 · Ines Esteves Domingues Pires da Silva, Ronen Stoff, et al. · Journal of Clinical Oncology
PDF
ADAPT-M: A tool to predict individualized benefit from adjuvant anti–PD-1 (PD-1) in resected high-risk melanoma.
2026 · Ines Esteves Domingues Pires da Silva, Susana Puig, et al. · Journal of Clinical Oncology
PDF
85P HPK1 inhibition enhances tumor-reactive TIL expansion from pMMR colorectal cancer liver metastases
2025 · L.P. del Carpio Huerta, A. Muñoz-Merino, et al. · Immuno-Oncology Technology
PDF
Abstract B003: Enhancing anti-tumoral reactivity with iHPK1 in liver metastasis to revitalize TIL product for therapy
2025 · Luis P. Del Carpio Huerta, Ainhoa Muñoz, et al. · Cancer Immunology Research
Works count: 46
Citation count: 357
H-index: 10
I10-index: 10
Year
Topic
Type